This Is The First Study Using Escalating Doses Of PF-03758309, An Oral Compound, In Patients With Advanced Solid Tumors

NCT00932126

Last updated date
Study Location
Pfizer Investigational Site
Santa Monica, California, 90404, United States
Contact
1-800-718-1021

FOR MORE INFORMATION

Contact a representative by phone, email, or visiting the study website. Please see the references below:

By phone

Pfizer Clinical Trials Contact Center

1-800-718-1021

By email

Contact

[email protected]

Call Now

Eligibility Criteria
condition
The disease, disorder, syndrome, illness, or injury that is being studied.
Advanced Solid Tumors
Sex
Females and Males
Age
Pediatric Trials: 0-17 Years
Adult Trials: 18+ Years
18 + years
Inclusion Criteria
The factors, or reasons, that allow a person to participate in a clinical study.
Show details

- Advanced/metastatic solid tumor that is resistant to standard therapy or for which no standard therapy is available.

- ECOG (Eastern Cooperative Oncology Group) Performance Status (PS) must be 0 or 1.

- Adequate bone marrow, liver and kidney function.

Exclusion Criteria
The factors, or reasons, that prevent a person from participating in a clinical study.
Show details


- Patients with known brain metastases.


- Previous high dose chemotherapy requiring stem cell rescue.


- Prior irradiation to >25% of the bone marrow.


- Active bacterial, fungal or viral infection including hepatitis B (HBV), hepatitis C
(HCV).


- Current active treatment in another clinical study.


- Pregnancy or breast feeding.


- Active inflammatory gastrointestinal disease, chronic diarrhea (unless related to
underlying malignancy or prior related treatment) or history of abdominal fistula,
gastrointestinal perforation, peptic ulcer disease, or intra-abdominal abscess within
6 months prior to study enrollment.

NEED INFO?

Questions about a trial? Call or email to reach a Pfizer Clinical Trial Contact Center Representative

Pfizer Clinical Trials Contact Center

1-800-718-1021

[email protected]

pfizer-logoClinical Trials
Interested in learning more about clinical trials?
Discover how clinical trials work and the impact your participation could have.

TRY A NEW SEARCH

Search for Clinical Trials by condition, keyword or trial number. Share your location or enter your city or zip code to find studies near you.

Based on your search, you may also be interested in

Advanced Solid TumorsA Bioequivalence Study Between the Proposed and Current Talazoparib Capsule Formulation and Food Effect Study for the Proposed Talazoparib Capsule Formulation in Participants With Advanced Solid Tumors
NCT04672460
  1. New Lambton Heights, New South Wales
  2. New Lambton Heights, New South Wales
  3. Downey, California
  4. Encinitas, California
  5. Glendale, California
  6. Long Beach, California
  7. Los Angeles, California
  8. Los Angeles, California
  9. Santa Ana, California
  10. Whittier, California
  11. Whittier, California
  12. New Haven, Connecticut
  13. New Haven, Connecticut
  14. New Haven, Connecticut
  15. Lake Mary, Florida
  16. Kansas City, Missouri
  17. Bronx, New York
  18. Cincinnati, Ohio
  19. Cleveland, Ohio
  20. West Chester, Ohio
  21. Pittsburgh, Pennsylvania
  22. Pittsburgh, Pennsylvania
  23. Pittsburgh, Pennsylvania
  24. Dallas, Texas
  25. San Antonio, Texas
  26. Liverpool, New South Wales
  27. Liverpool, New South Wales
ALL GENDERS
18 Years+
years
MULTIPLE SITES
Advanced Solid TumorsA Study of Temsirolimus Plus Capecitabine in Patients With Advanced Cancer
NCT01050985
  1. Washington, District of Columbia
ALL GENDERS
18 Years+
years
MULTIPLE SITES
Advanced Solid TumorsA Study of ARRY-382 in Combination With Pembrolizumab for the Treatment of Patients With Advanced Solid Tumors
NCT02880371
  1. Los Angeles, California
  2. Los Angeles, California
  3. Santa Monica, California
  4. Aurora, Colorado
  5. Aurora, Colorado
  6. Port Saint Lucie, Florida
  7. Fort Wayne, Indiana
  8. Fort Wayne, Indiana
  9. Fort Wayne, Indiana
  10. Fort Wayne, Indiana
  11. Lafayette, Indiana
  12. Cedar Rapids, Iowa
  13. Boston, Massachusetts
  14. Boston, Massachusetts
  15. Boston, Massachusetts
  16. Boston, Massachusetts
  17. Detroit, Michigan
  18. Rochester, Minnesota
  19. Saint Paul, Minnesota
  20. Saint Paul, Minnesota
  21. Saint Paul, Minnesota
  22. Saint Paul, Minnesota
  23. Nashville, Tennessee
  24. Nashville, Tennessee
  25. Nashville, Tennessee
  26. San Antonio, Texas
  27. Salt Lake City, Utah
  28. Salt Lake City, Utah
  29. Charlottesville, Virginia
  30. Charlottesville, Virginia
ALL GENDERS
18 Years+
years
MULTIPLE SITES
Advanced Solid TumorsA Study of Talazoparib in Patients With Advanced Solid Tumors
NCT03070548
  1. Budapest,
ALL GENDERS
18 Years+
years
MULTIPLE SITES
Advanced Information
Descriptive Information
Brief Title  ICMJE This Is The First Study Using Escalating Doses Of PF-03758309, An Oral Compound, In Patients With Advanced Solid Tumors
Official Title  ICMJE Phase 1, Open Label, Dose-Escalation, Safety, Pharmacokinetic And Pharmacodynamic Study Of Single Agent PF-03758309, An Oral PAK4 Inhibitor, In Patients With Advanced Solid Tumors
Brief Summary This is the first study using PF-03758309, an oral compound, in patients with advanced solid tumors. In this study different doses of PF-03758309 will be administered to different groups of patients. The study will assess the compound's safety, the blood levels of PF-03758309 during the treatment and the effect of the compound on the tumor cells.
Detailed Description The study was prematurely terminated on 26Jul2011 due to the undesirable PK characteristics of PF-03758309 and the lack of an observed dose-response relationship. There were no safety concerns that contributed to the study termination.
Study Type  ICMJE Interventional
Study Phase  ICMJE Phase 1
Study Design  ICMJE Allocation: Non-Randomized
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Condition  ICMJE Advanced Solid Tumors
Intervention  ICMJE Drug: PF-03758309
Oral PF-03758309 will be administered in capsules (once or twice daily) until toxicity, progressive disease, or patient refusal to continue on therapy. The starting dose is 1 mg once daily.
Study Arms  ICMJE Experimental: 1
Intervention: Drug: PF-03758309
Publications * Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Recruitment Information
Recruitment Status  ICMJE Terminated
Actual Enrollment  ICMJE
 (submitted: September 24, 2012)
35
Original Estimated Enrollment  ICMJE
 (submitted: July 2, 2009)
50
Actual Study Completion Date  ICMJE December 2011
Actual Primary Completion Date December 2011   (Final data collection date for primary outcome measure)
Eligibility Criteria  ICMJE

Inclusion Criteria:

  • Advanced/metastatic solid tumor that is resistant to standard therapy or for which no standard therapy is available.
  • ECOG (Eastern Cooperative Oncology Group) Performance Status (PS) must be 0 or 1.
  • Adequate bone marrow, liver and kidney function.

Exclusion Criteria:

  • Patients with known brain metastases.
  • Previous high dose chemotherapy requiring stem cell rescue.
  • Prior irradiation to >25% of the bone marrow.
  • Active bacterial, fungal or viral infection including hepatitis B (HBV), hepatitis C (HCV).
  • Current active treatment in another clinical study.
  • Pregnancy or breast feeding.
  • Active inflammatory gastrointestinal disease, chronic diarrhea (unless related to underlying malignancy or prior related treatment) or history of abdominal fistula, gastrointestinal perforation, peptic ulcer disease, or intra-abdominal abscess within 6 months prior to study enrollment.
Sex/Gender  ICMJE
Sexes Eligible for Study:All
Ages  ICMJE 18 Years and older   (Adult, Older Adult)
Accepts Healthy Volunteers  ICMJE No
Contacts  ICMJE Contact information is only displayed when the study is recruiting subjects
Listed Location Countries  ICMJE Australia,   United States
Removed Location Countries  
 
Administrative Information
NCT Number  ICMJE NCT00932126
Other Study ID Numbers  ICMJE B1301001
Has Data Monitoring Committee No
U.S. FDA-regulated Product Not Provided
IPD Sharing Statement  ICMJE Not Provided
Responsible Party Pfizer
Study Sponsor  ICMJE Pfizer
Collaborators  ICMJE Not Provided
Investigators  ICMJE
Study Director:Pfizer CT.gov Call CenterPfizer
PRS Account Pfizer
Verification Date October 2015

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP